Lonza Biologics Ltd
About Company
Established in May 2019, Lonza Biologics Ltd. is another wholly owned enterprise of Lonza Group in China. The company has completed the construction of its strategic biomanufacturing base in Sino-Singapore Knowledge City of Guangzhou Development Zone (SSGKC), and started up in Q2, 2021. This multifunctional site offers both clinical and commercial supply with an area of 17,000m2 including 6,500m2 of lab space and one KUBio facility. As Lonza’s ninth biologics facility, the Guangzhou site will extend Lonza Pharma & Biotech’s global biologics network that provides customers with integrated solutions from pre-clinical development to commercial production, to address the growing demand for high-quality CDMO services in China.
Building on Lonza Group’s outstanding track record of BLA and MAA and international regulatory expertise, combined with global standards of technological and operational excellence, Lonza Biologics Ltd. will offer Lonza’s leading biomanufacturing services to Chinese customers, and further benefit more patients.